CORRECTION



Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

David Elsea¹ · Lin Fan² · Adela Mihai³ · Fadoua El Moustaid¹ · Daniel Simmons⁴ · Matthew Monberg⁵ · Dominic Muston⁵

Published online: 15 September 2022 © The Author(s) 2022

Correction to: PharmacoEconomics - Open https://doi.org/10.1007/s41669-022-00338-2

In this article, the corresponding author was incorrectly listed as Lin Fan.

It should have been Dominic Muston.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction

The original article can be found online at https://doi.org/10.1007/s41669-022-00338-2.

☐ Dominic Muston dominic.muston@merck.com

David Elsea david.d.elsea@gmail.com

Lin Fan fanlinaaron@gmail.com

Adela Mihai Adela.mihai@astrazeneca.com

Fadoua El Moustaid ms.fadoua@gmail.com

Daniel Simmons daniel.simmons@astrazeneca.com

Matthew Monberg matthew.monberg@merck.com

- ¹ Formerly of Lumanity, Inc., Bethesda, MD 20814, USA
- ² Formerly of Merck & Co., Inc., Rahway, NJ 07065, USA
- AstraZeneca, Cambridge, UK
- ⁴ AstraZeneca, Gaithersburg, MD, USA
- ⁵ Merck & Co., Inc., Rahway, NJ 07065, USA

in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.